E2-CD154 vaccine candidate is safe and immunogenic in pregnant sows, and the maternal derived neutralizing antibodies protect piglets from classical swine fever virus challenge

2021 ◽  
pp. 109153
Author(s):  
Danny Pérez-Pérez ◽  
Yusmel Sordo-Puga ◽  
María Pilar Rodríguez-Moltó ◽  
Talía Sardina ◽  
Elaine Santana ◽  
...  
Keyword(s):  
Classical Swine Fever Virus ◽  
Neutralizing Antibodies ◽  
Vaccine Candidate ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
Virus Challenge

scholarly journals A Novel E2 Glycoprotein Subunit Marker Vaccine Produced in Plant Is Able to Prevent Classical Swine Fever Virus Vertical Transmission after Double Vaccination

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 418
Author(s):  
Youngmin Park ◽  
Yeonsu Oh ◽  
Miaomiao Wang ◽  
Llilianne Ganges ◽  
José Alejandro Bohórquez ◽  
...  
Keyword(s):  
Vertical Transmission ◽  
Classical Swine Fever Virus ◽  
Neutralizing Antibodies ◽  
Subunit Vaccine ◽  
Vaccine Dose ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
Tissue Samples ◽  
Marker Vaccine ◽  
E2 Glycoprotein

The efficacy of a novel subunit vaccine candidate, based in the CSFV E2 glycoprotein produced in plants to prevent classical swine fever virus (CSFV) vertical transmission, was evaluated. A Nicotiana benthamiana tissue culture system was used to obtain a stable production of the E2-glycoprotein fused to the porcine Fc region of IgG. Ten pregnant sows were divided into three groups: Groups 1 and 2 (four sows each) were vaccinated with either 100 μg/dose or 300 μg/dose of the subunit vaccine at 64 days of pregnancy. Group 3 (two sows) was injected with PBS. Groups 1 and 2 were boosted with the same vaccine dose. At 10 days post second vaccination, the sows in Groups 2 and 3 were challenged with a highly virulent CSFV strain. The vaccinated sows remained clinically healthy and seroconverted rapidly, showing efficient neutralizing antibodies. The fetuses from vaccinated sows did not show gross lesions, and all analyzed tissue samples tested negative for CSFV replication. However, fetuses of non-vaccinated sows had high CSFV replication in tested tissue samples. The results suggested that in vaccinated sows, the plant produced E2 marker vaccine induced the protective immunogenicity at challenge, leading to protection from vertical transmission to fetuses.

scholarly journals Identification of E2 with improved secretion and immunogenicity against CSFV in piglets

2020 ◽  
Author(s):  
Huiling Xu ◽  
Yanli Wang ◽  
Guangwei Han ◽  
Weihuan Fang ◽  
fang he
Keyword(s):  
Single Dose ◽  
Signal Peptide ◽  
Classical Swine Fever Virus ◽  
Subunit Vaccine ◽  
Classical Swine Fever ◽  
Cost Effective ◽  
Fever Virus ◽  
Economic Losses ◽  
Swine Industry ◽  
Virus Challenge

Abstract Background: Outbreaks of Classical swine fever virus (CSFV) cause significant economic losses in the swine industry. Vaccination is the major method to prevent and control the disease. As live attenuated vaccines fail to elicit differentiable immunity between infected and vaccinated animals, subunit vaccine was considered as an alternative candidate to prevent and eradicate CSFV. Subunit vaccines present advantages in DIVA immunogenicity and safety. The technology was limited due to the low yield and the high cost with multiple and large doses. The native E2 signal peptide has not been well defined before. Here, the aim of this study is to develop a cost-effective and efficacious E2 vaccine candidate against CSFV with signal peptide and E2 sequence selection. Results: A novel CSFV E2 sequence (E2ZJ) was identified from an epidemic strain of Zhejiang for outstanding secretion in baculovirus and enhanced immunogenicity. E2 secretion induced with the selected signal peptide, SPZJ (SP23), increase at least 50% as compared to any other signal peptides tested. Besides, unique antigenic features were identified in E2ZJ. E2ZJ elicited CSFV antibodies at the earlier stage than other E2 types tested in mice. Moreover, higher level of neutralization antibodies against both genotypes 1 and 2 CSFV with E2ZJ was detected than other E2s with the same dosage. Further, in piglets, E2ZJ successfully elicited neutralizing immunity. A single dose of 5 μg of E2ZJ was sufficient to induce protective antibodies against CSFV in piglets and provided 100% protection against lethal virus challenge. Conclusions: Our studies provide evidence that E2ZJ guided by a novel E2 signal peptide (SPZJ) was efficiently secreted and presented significantly improved immunogenicity than conventional E2 vaccines. Moreover, a single dose of 5 μg E2ZJ is efficacious against CSFV in piglets. Keywords: Classical swine fever virus; novel signal peptide; SPZJ-E2ZJ; subunit vaccine; protective immunity

Immunogenicity of a lettuce-derived vaccine candidate expressing the E2 protein against classical swine fever virus

2013 ◽  
Vol 113 (3) ◽  
pp. 483-490 ◽  
Author(s):  
Jinn-Chin Yiu ◽  
Cheng-Wei Liu ◽  
Ruei-Yuan Su ◽  
Wan-Jun Lai ◽  
Menq-Jiau Tseng ◽  
...  
Keyword(s):  
Classical Swine Fever Virus ◽  
Vaccine Candidate ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
E2 Protein

A novel dendrimeric peptide induces high level neutralizing antibodies against classical swine fever virus in rabbits

2012 ◽  
Vol 156 (1-2) ◽  
pp. 200-204 ◽  
Author(s):  
Guo-Xin Li ◽  
Yan-Jun Zhou ◽  
Hai Yu ◽  
Ling Li ◽  
Ya-Xin Wang ◽  
...  
Keyword(s):  
Classical Swine Fever Virus ◽  
Neutralizing Antibodies ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
High Level

Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes

2014 ◽  
Vol 169 (1-2) ◽  
pp. 8-17 ◽  
Author(s):  
Sandra Blome ◽  
Claudia Gabriel ◽  
Stefanie Schmeiser ◽  
Denise Meyer ◽  
Alexandra Meindl-Böhmer ◽  
...  
Keyword(s):  
Classical Swine Fever Virus ◽  
Vaccine Candidate ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
Marker Vaccine ◽  
Virus Isolates

scholarly journals Effectiveness of the E2-Classical Swine Fever Virus Recombinant Vaccine Produced and Formulated within Whey from Genetically Transformed Goats

2014 ◽  
Vol 21 (12) ◽  
pp. 1628-1634 ◽  
Author(s):  
O. Sánchez ◽  
M. Barrera ◽  
O. Farnós ◽  
N. C. Parra ◽  
E. R. Salgado ◽  
...  
Keyword(s):  
Classical Swine Fever Virus ◽  
Neutralizing Antibodies ◽  
Adverse Reactions ◽  
Clinical Signs ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
Minor Amount ◽  
Lethal Challenge ◽  
Promising Alternative ◽  
A Minor

ABSTRACTSubunit recombinant vaccines against classical swine fever virus (CSFV) are a promising alternative to overcome practical and biosafety issues with inactivated vaccines. One of the strategies in evaluation under field conditions is the use of a new marker E2-based vaccine produced in the milk of adenovirally transduced goats. Previously we had demonstrated the efficacy of this antigen, which conferred early protection and long-lasting immunity in swine against CSFV infection. Here, we have used a simpler downstream process to obtain and formulate the recombinant E2 glycoprotein expressed in the mammary gland. The expression levels reached approximately 1.7 mg/ml, and instead of chromatographic separation of the antigen, we utilized a clarification process that eliminates the fat content, retains a minor amount of caseins, and includes an adenoviral inactivation step that improves the biosafety of the final formulation. In a vaccination and challenge experiment in swine, different doses of the E2 antigen contained within the clarified whey generated an effective immune response of neutralizing antibodies that protected all of the animals against a lethal challenge with CSFV. During the immunization and after challenge, the swine were monitored for adverse reactions related to the vaccine or symptoms of CSF, respectively. No adverse reactions or clinical signs of disease were observed in vaccinated animals, in which no replication of CSFV could be detected after challenge. Overall, we consider that the simplicity of the procedures proposed here is a further step toward the introduction and implementation of a commercial subunit vaccine against CSF.

scholarly journals Generation and Efficacy Evaluation of a Recombinant Pseudorabies Virus Variant Expressing the E2 Protein of Classical Swine Fever Virus in Pigs

2015 ◽  
Vol 22 (10) ◽  
pp. 1121-1129 ◽  
Author(s):  
Yimin Wang ◽  
Jin Yuan ◽  
Xin Cong ◽  
Hua-Yang Qin ◽  
Chun-Hua Wang ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Classical Swine Fever Virus ◽  
Neutralizing Antibodies ◽  
Pseudorabies Virus ◽  
Classical Swine Fever ◽  
Fever Virus ◽  
Complete Protection ◽  
Efficacy Evaluation ◽  
Lethal Challenge ◽  
Recombinant Pseudorabies Virus

ABSTRACTClassical swine fever (CSF) is an economically important infectious disease of pigs caused by classical swine fever virus (CSFV). Pseudorabies (PR), which is caused by pseudorabies virus (PRV), is another important infectious disease of pigs and other animals. Coinfections of pigs with PRV and CSFV occur occasionally in the field. The modified live vaccine Bartha-K61 strain has played an important role in the control of PR in many countries, including China. Since late 2011, however, increasing PR outbreaks caused by an emerging PRV variant have been reported in Bartha-K61-vaccinated swine populations on many farms in China. Previously, we generated a gE/gI-deleted PRV (rPRVTJ-delgE) based on this PRV variant, which was shown to be safe and can provide rapid and complete protection against lethal challenge with the PRV variant in pigs. Here, we generated a new recombinant PRV variant expressing the E2 gene of CSFV (rPRVTJ-delgE/gI-E2) and evaluated its immunogenicity and efficacy in pigs. The results showed that rPRVTJ-delgE/gI-E2 was safe for pigs, induced detectable anti-PRV and anti-CSFV neutralizing antibodies, and provided complete protection against the lethal challenge with either the PRV TJ strain or the CSFV Shimen strain. The data indicate that rPRVTJ-delgE/gI-E2 is a promising candidate bivalent vaccine against PRV and CSFV coinfections.

scholarly journals Development of an Alphavirus Replicon Classical Swine Fever Virus Vaccine Candidate

2013 ◽  
Author(s):  
J. Dustin Loy ◽  
Mark Mogler ◽  
Jill Gander ◽  
Kurt I. Kamrud ◽  
D.L. Hank Harris
Keyword(s):  
Virus Vaccine ◽  
Classical Swine Fever Virus ◽  
Vaccine Candidate ◽  
Classical Swine Fever ◽  
Fever Virus
Sign in / Sign up

Export Citation Format

Share Document